A Phase 3, Open-Label, Randomized, Long-Term Comparison of the Safety and Tolerability of the TAK-491 Plus Chlorthalidone Fixed-Dose Combination vs. Olmesartan Medoxomil-Hydrochlorothiazide Fixed-Dose Combination in Subjects With Essential Hypertension.

Trial Profile

A Phase 3, Open-Label, Randomized, Long-Term Comparison of the Safety and Tolerability of the TAK-491 Plus Chlorthalidone Fixed-Dose Combination vs. Olmesartan Medoxomil-Hydrochlorothiazide Fixed-Dose Combination in Subjects With Essential Hypertension.

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Jul 2017

At a glance

  • Drugs Azilsartan medoxomil/chlortalidone (Primary) ; Olmesartan medoxomil/hydrochlorothiazide
  • Indications Essential hypertension
  • Focus Adverse reactions; Pharmacogenomic; Registrational
  • Most Recent Events

    • 06 Jul 2017 Results published in the Journal of Clinical Hypertension (Greenwich)
    • 04 Oct 2012 Results presented at the 24th Scientific Meeting of the International Society of Hypertension.
    • 29 Mar 2012 Planned number of patients changed from 837 to 880 as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top